Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2007

Psychogenics and Cephalon Ally on Neuropsychiatric Drug Discovery

  • PsychoGenics entered into a drug discovery agreement with Cephalon related to neuropsychiatric disorders. Cephalon will provide related compounds, while Psycogenics will evaluate these candidates.

    The companies will jointly identify those candidates suitable for clinical development. If either company decides to further develop any of these drugs, that firm will pay the other milestone and royalty fees .

    PsychoGenics' technologies combines in vivo behavioral expertise with robotics, computer vision, and bio/cheminformatics. The platform is used to evaluate potential therapies related to a number of neuropsychiatric disease indications.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »